<DOC>
	<DOCNO>NCT00645437</DOCNO>
	<brief_summary>The primary objective evaluate pharmacokinetics safety two dose regimen levofloxacin patient vary degree renal function .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Safety Levofloxacin Patients With Varying Degrees Renal Function .</brief_title>
	<detailed_description>In multiple-dose study conduct 4 center , pharmacokinetics two dose regimen levofloxacin assess medically stable men woman vary degree renal function . The study consist 21 day pretreatment screen phase , 7-day open label treatment phase , 7 day posttreatment phase ( follow-up phase subject early study withdrawal ) . Patients randomize 1 10 treatment group , total 6 patient per group , base degree renal function ensure creatinine clearance value within group represent full range value define Food Drug Administration 's ( FDA ) 1998 guideline pharmacokinetic study patient impaired renal function . Fifty-nine patient enrol study . All patient receive single 750-mg dose levofloxacin Day 1 ; subsequent dose either 250 , 500 , 750 mg levofloxacin ( q24h q48h ) base renal function . Blood sample collect patient Day 1 Day 14 pharmacokinetic evaluation . Urine collect Days 1 7 dose specific time interval 24 48 hour postdosing depend patient 's dose regimen . Dialysate sample collect Day 7 HD patient immediately dose ( dialysis begin ) end dialysis treatment . Patients confine overnight study unit Days 0 , 1 , 6 , 7 , remain confined 24 hour blood sample collect Days 2 8 . Safety base incidence , relationship therapy , severity treatment-emergent adverse event change clinical laboratory value ( hematology , chemistry , urinalysis ) , vital sign measurement , electrocardiogram ( ECGs ) , physical examination finding . Single 750-mg dose levofloxacin Day 1 ; subsequent dos Levofloxacin 250 milligram ( mg ) , 500 mg , 750 mg tablet administer every 24 hour 7 day every 48 hour 7 day</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>BMI 18 35 kg/m2 No prescription overthecounter medication previous 7 day Negative test drug alcohol abuse , HIV , hepatitis B hepatitis C Medically stable base medical history , physical examination , 12lead electrocardiogram , toxicology , antigen , antibody screen , clinical laboratory evaluation Stable renal function base calculated creatine clearance nondialysis patient dialysis treatment least 6 month prior screen dialysis patient Patients creatinine clearance =80 mL/min require treatment renal impairment chronic disease ( e.g. , wellcontrolled diabetes , hypertension ) must stable treatment plan ( medicine , dos , regimen ) least 2 month prior Day 1 entire study Hematocrit ( hct ) within normal range base patient ' renal function screen Allergic reaction quinolones Known suspect allergy heparin Clinically significant ECG clinical laboratory abnormality Creatinine clearance &lt; 80 mL/min whose medical condition unstable creatinine clearance &gt; = 80 mL/min require concomitant medication study Poorly control type 1 type 2 diabetes Patients creatinine clearance &gt; = 50 mL/min screen blood pressure outside normal range ( sit systolic blood pressure &lt; 90 &gt; 140 mm mercury [ Hg ] diastolic blood pressure &lt; 60 &gt; 90 mm Hg ) Patients CLCR &lt; 50 mL/min sit systolic blood pressure &lt; 90 &gt; 160 mm Hg , diastolic blood pressure &lt; 60 &gt; 90 mm Hg Required warfarin treatment Required immunosuppressive medication treatment immunemediated renal disease kidney transplant Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>renal disease</keyword>
	<keyword>levofloxacin</keyword>
</DOC>